Recent evidence reports that transient BAP1 mutation increases the sensitivity of MM cell lines to HDAC inhibitors, as opposed to long-term BAP1 loss where adaptation had reduced sensitivity [51]. The gene discussed is BAP1; the disease is Miyoshi myopathy.